Skip to main content

NGM Biopharmaceuticals Inc

NGMDelisted Apr 5, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001426332

NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.

Q1 2024 vs. Q4 2023

How the institutions holding NGM Biopharmaceuticals Inc changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of NGM: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders8375−8
Shares41.1M34.6M−6.50M (−15.8%)
Value$35.3M$55.1M+$19.8M (+56.1%)

New holders (15)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to NGM in Q1 2024
InstitutionSharesValue% of portfolio
Trium Capital LLP977,965$1.55M0.58%
ADAR1 Capital Management, LLC816,581$1.30M0.35%
Balyasny Asset Management LLC360,599$573.4K0.00%
Natixis181,366$288.4K0.00%
Connor, Clark & Lunn Investment Management Ltd.98,037$155.9K0.00%
Mirae Asset Global Investments Co., Ltd.21,169$80.9K0.00%
Virtu Financial LLC48,708$77.0K0.01%
Diker Management LLC29,996$47.7K0.04%
Oxford Asset Management LLP19,458$30.9K0.03%
AQR Capital Management LLC16,963$27.0K0.00%
Cubist Systematic Strategies, LLC15,910$25.3K0.00%
JustInvest LLC11,644$18.5K0.00%
Capital Advisors, Ltd. LLC777$1.00K0.00%
Farther Finance Advisors, LLC96$1500.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC7$110.00%

Sold out (23)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q4 2023 and filed for Q1 2024 without it.